The stock has rebounded

Stocks got a leg up Thursday as investors, faced with mixed economic data, focused more on the good news — strong home sales — and shrugged off the bad — higher-than-expected initial jobless claims.
Pending home sales jumped by a much-better-than-expected 4% in March. Economists had expected a 0.5% gain. New jobless claims fell 1,000 to a seasonally adjusted 388,000 last week, worse than forecasts for 375,000.
The Dow Jones industrial average added 0.9%, while the Nasdaq and the S&P 500 each gained 0.7%.
Volume climbed 5% on the Nasdaq but fell 4% on the NYSE, according to preliminary data.
Equinix (EQIX) surged 13% in fast turnover. Late Wednesday, the provider of high-performance data centers said first-quarter EPS increased 34% to 71 cents, crushing forecasts for 49 cents. Revenue grew 25% to $452 million. The stock has rebounded off its 10-week moving average to a new high after making its first pullback to that level since a breakout in January.

Texas Capital Bancshares (TCBI) jumped 7% in fast trade, clearing a 36.71 buy point from a square-box base. The regional bank said quarterly EPS climbed 126% to 70 cents, beating views, as sales rose 32% to $102 million. It also scored an upgrade to buy from Sterne Agee.
SolarWinds (SWI) shot up 20% in huge turnover after gapping above its 50-day line to an all-time high. The software maker said quarterly EPS grew 43% to 30 cents, topping forecasts and accelerating from a 21% jump in the fourth quarter of 2011. Revenue, including acquisitions, jumped 39% to $59.7 million. SolarWinds has lifted off support at its 10-week moving average.
O'Reilly Automotive (ORLY) leapt 6% in strong volume and notched a new high before giving up some gains. The car parts retailer said quarterly EPS gained 37% to $1.14, ahead of estimates, as revenue jumped 11% to $1.5 billion. Its guidance was roughly in line. The stock hit a new high early Thursday, but has given up gains. It's well-extended past its last buying range.
But Nu Skin Enterprises (NUS) fell 7% despite topping views. Before the open, the maker of skin care products reported that its Q1 profit climbed 32% to 74 cents a share vs. expectations of 70 cents. Revenue grew 17% to $462 million, also above estimates. But Nu Skin sees Q2 earnings coming in at 79 cents to 83 cents a share, below expectations of 85 cents.
Celgene (CELG) gapped below its 50-day moving average and dropped 5% after reporting disappointing Q1 results. The biotech earned $1.08 a share, up 30% from a year ago. But it missed views by a nickel. Sales rose 13% to $1.27 billion, below expectations and the smallest increase in 11 quarters. It was also the fourth straight quarter of sales growth deceleration.